HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Gianpietro Dotti Selected Research

I-E-antigen

10/2018CD30-Redirected Chimeric Antigen Receptor T Cells Target CD30+ and CD30- Embryonal Carcinoma via Antigen-Dependent and Fas/FasL Interactions.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Gianpietro Dotti Research Topics

Disease

126Neoplasms (Cancer)
03/2022 - 07/2002
12Neuroblastoma
11/2020 - 11/2008
10Hematologic Neoplasms (Hematological Malignancy)
01/2021 - 09/2008
10Graft vs Host Disease (Graft-Versus-Host Disease)
04/2016 - 11/2003
9Lymphoma (Lymphomas)
11/2021 - 10/2002
8Melanoma (Melanoma, Malignant)
01/2022 - 09/2008
8Leukemia
01/2016 - 02/2003
7Hodgkin Disease (Hodgkin's Disease)
01/2022 - 10/2007
7B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
11/2021 - 04/2003
7Glioblastoma (Glioblastoma Multiforme)
10/2021 - 01/2016
5Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
01/2022 - 11/2013
4Multiple Myeloma
03/2019 - 01/2002
4Infections
06/2015 - 10/2002
3Lung Neoplasms (Lung Cancer)
01/2022 - 01/2018
3Brain Neoplasms (Brain Tumor)
01/2022 - 12/2011
3Neoplasm Metastasis (Metastasis)
01/2021 - 01/2018
3Sarcoma (Soft Tissue Sarcoma)
12/2020 - 05/2015
3Breast Neoplasms (Breast Cancer)
01/2020 - 06/2007
3Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2020 - 11/2014
3Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
12/2019 - 01/2019
2Hyperthermia
06/2019 - 06/2015
2Cytokine Release Syndrome
12/2018 - 06/2015
2Glioma (Gliomas)
01/2017 - 02/2016
2Virus Diseases (Viral Diseases)
10/2013 - 08/2009
2Persistent Infection
12/2011 - 07/2011
2B-Cell Lymphoma (Lymphoma, B Cell)
05/2011 - 12/2006
2Testicular Neoplasms (Testicular Cancer)
03/2011 - 09/2008
2Non-Hodgkin Lymphoma (Lymphosarcoma)
06/2008 - 12/2006
1Small Cell Lung Carcinoma (Small Cell Lung Cancer)
01/2022
1Osteosarcoma (Osteogenic Sarcoma)
01/2022

Drug/Important Bio-Agent (IBA)

81Chimeric Antigen ReceptorsIBA
03/2022 - 11/2005
46AntigensIBA
01/2022 - 07/2002
11CytokinesIBA
11/2021 - 10/2007
11Interleukin-15 (Interleukin 15)IBA
01/2021 - 10/2007
9Neoplasm Antigens (Tumor Antigens)IBA
01/2022 - 04/2003
8Interleukin-2 (IL2)IBA
06/2014 - 10/2005
7Monoclonal AntibodiesIBA
01/2020 - 03/2005
6VaccinesIBA
01/2019 - 04/2003
5CD40 Ligand (CD40L)IBA
10/2011 - 07/2002
4chondroitin sulfate proteoglycan 4IBA
01/2021 - 01/2015
4Pharmaceutical PreparationsIBA
12/2020 - 11/2011
4Cyclophosphamide (Cytoxan)FDA LinkGeneric
12/2018 - 06/2015
4Proteins (Proteins, Gene)FDA Link
05/2015 - 04/2003
3T-Cell Antigen Receptors (T-Cell Receptor)IBA
01/2022 - 01/2015
3Ki-1 AntigenIBA
01/2022 - 06/2009
3Immunoglobulins (Immunoglobulin)IBA
11/2021 - 10/2005
3B7-H1 AntigenIBA
01/2021 - 01/2018
3fludarabineIBA
11/2020 - 06/2015
3GD2 gangliosideIBA
10/2020 - 09/2009
3ErbB Receptors (EGF Receptor)IBA
01/2020 - 12/2011
3Immune Checkpoint InhibitorsIBA
01/2020 - 01/2018
3EpitopesIBA
01/2019 - 04/2012
3ChemokinesIBA
01/2018 - 06/2009
3Therapeutic UsesIBA
01/2018 - 08/2010
3AP 1903 reagentIBA
04/2016 - 11/2011
3Caspase 9IBA
04/2016 - 11/2014
3CD19-specific chimeric antigen receptorIBA
01/2016 - 10/2013
3Interleukin-7 (Interleukin 7)IBA
06/2014 - 05/2009
2Interleukin-12 (IL 12)IBA
01/2022 - 01/2018
2InterferonsIBA
01/2022 - 12/2021
2FibrinIBA
10/2021 - 01/2019
2HydrogelsIBA
01/2021 - 10/2020
2vadimezanIBA
01/2021 - 01/2021
2Cancer VaccinesIBA
12/2020 - 01/2019
2Doxorubicin (Adriamycin)FDA LinkGeneric
12/2020 - 01/2018
2InterleukinsIBA
10/2020 - 01/2013
2Panitumumab (Vectibix)FDA Link
01/2020 - 01/2020
2Interferon-gamma (Interferon, gamma)IBA
01/2020 - 11/2005
2Cetuximab (Erbitux)FDA Link
01/2020 - 01/2020
2Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
01/2020 - 01/2018
2Chondroitin Sulfates (Chondroitin Sulfate)IBA
06/2019 - 02/2014
2AntibodiesIBA
01/2019 - 10/2014
2Transforming Growth Factors (Transforming Growth Factor)IBA
10/2018 - 06/2008
2CD19 AntigensIBA
01/2017 - 05/2011
2human ERBB2 proteinIBA
05/2015 - 06/2007
2Chemokine CCL5IBA
02/2015 - 09/2014
2AutoantigensIBA
01/2015 - 07/2002
2Biological ProductsIBA
09/2014 - 11/2012
2Viral AntigensIBA
10/2013 - 12/2011
2Antiviral Agents (Antivirals)IBA
10/2013 - 04/2010
2LigandsIBA
06/2009 - 03/2005
1VimentinIBA
01/2022
1CCR2 ReceptorsIBA
01/2022
1Enhancer of Zeste Homolog 2 ProteinIBA
01/2022
1Antineoplastic Agents (Antineoplastics)IBA
01/2022
1tazemetostatIBA
01/2022
1Adenosine Triphosphate (ATP)IBA
12/2021
1Immunoglobulin Light Chains (Immunoglobulin Light Chain)IBA
11/2021

Therapy/Procedure

48Immunotherapy
01/2021 - 07/2002
46Therapeutics
03/2022 - 03/2005
6Drug Therapy (Chemotherapy)
12/2019 - 10/2002
5Transplantation
11/2015 - 11/2003
5Stem Cell Transplantation
11/2011 - 08/2007
4Hematopoietic Stem Cell Transplantation
11/2015 - 11/2003
2Cell- and Tissue-Based Therapy (Cell Therapy)
01/2022 - 12/2021
2Intravenous Infusions
01/2022 - 07/2009
2Intravenous Administration
10/2021 - 01/2021
2Radiotherapy
01/2021 - 10/2014
2Injections
10/2020 - 10/2014
1Transjugular Intrahepatic Portasystemic Shunt
03/2022